investorrelations.sarepta.com Open in urlscan Pro
2a02:26f0:c6::210:6563 Public Scan

Back to summary

URL:
https://investorrelations.sarepta.com/events-presentations
Submission: On October 31 via api (October 31st 2023, 2:33:39 pm UTC) from US — Scanned from DE

Form analysis
1 forms found in the DOM

GET /search

<form action="/search" method="get" id="views-exposed-form-acquia-search-page" accept-charset="UTF-8">
  <div class="js-form-item form-item js-form-type-search-api-autocomplete form-item-search js-form-item-search form-no-label">
    <input data-drupal-selector="edit-search" data-search-api-autocomplete-search="acquia_search" class="form-autocomplete form-text" data-autocomplete-path="/search_api_autocomplete/acquia_search?display=page&amp;&amp;filter=search" type="text"
      id="edit-search" name="search" value="" size="30" maxlength="128">
  </div>
  <div data-drupal-selector="edit-actions" class="form-actions js-form-wrapper form-wrapper" id="edit-actions">
    <input class="success button radius js-form-submit form-submit" data-drupal-selector="edit-submit-acquia-search" type="submit" id="edit-submit-acquia-search" value="Search">
  </div>
</form>

Text Content

UTILITY MENU

* Investors
* Newsroom
* Contact Us

REGIONAL NAVIGATION

*
Global Sites
*
Switzerland
* Deutsch

* English

* Français

* Italiano

*
UK
* English

*
United States
* English

Toggle Menu Button

UTILITY MENU

* Investors
* Newsroom
* Contact Us

REGIONAL NAVIGATION

*
Global Sites
*
Switzerland
* Deutsch

* English

* Français

* Italiano

*
UK
* English

*
United States
* English

SOCIAL LINKS

* Twitter
* LinkedIn
* Instagram
* Facebook

MAIN NAVIGATION

* Our Disease Areas
* Duchenne Muscular Dystrophy
* Limb-girdle Muscular Dystrophy
* Charcot-Marie-Tooth Disease
* Our Science
* Gene Therapy Engine
* RNA Platform
* Gene Editing
* Manufacturing
* Strategic Partnerships
* Our Products & Pipeline
* Products
* Pipeline
* Clinical Trials
* Treatment Access
* About Us
* Leadership
* Patient Affairs
* Corporate Responsibility
* Grants & Giving
* Global Locations
* Contact Us
* Join Us
* Career Opportunities

Toggle Menu Button

EVENTS & PRESENTATIONS

* Home
* Investor Relations
* Events & Presentations

IR MENU

IR Home
Press Releases
Events & Presentations
Corporate Governance
Stock Information
SEC Filings
Analyst Coverage
Information Request
FAQs

EVENTS & PRESENTATIONS

UPCOMING EVENTS AND PRESENTATIONS

Date Title Supporting Materials 10/30/23 at 4:30 PM EDT
Sarepta Therapeutics Update
Click here for webcast
Sarepta EMBARK Part 1 Topline Investor Webcast Slides (FLS) 2.1 MB
11/01/23 at 4:30 PM EDT
Sarepta Therapeutics Third Quarter 2023 Earnings Call
Add to Outlook
Add to Google Calendar
Click here for webcast

ARCHIVED EVENTS AND PRESENTATIONS

Date Title Supporting Materials 10/03 - 10/07/23
28th Annual Congress of the World Muscle Society (WMS 2023)
P.23 Potter et al. Sequential PPMO to Gene Therapy 3.7 MB
P.24 Mercuri et al. Study 4658-102 OLE 661.6 KB
P.31 Ramos-Platt et al. EVOLVE in Young Patients 627.9 KB
P.41 Mason et al. EMBARK Study Design and Baseline Characteristics 446.9 KB
P.42 Proud et al. Practical Considerations for Del Mox Gtx in DMD 573.8 KB
P.46 Mercuri et al. ENVOL Ph2 OL trial in DMD 554.8 KB
P.47 Mercuri et al. ENVISION Ph3 Eval Safety and Efficacy of Del Mox in DMD 452
KB
P.54 Potter et al. IMM Epitope Mapping 1 MB
P.141 Lowes et al. PROMIS Concordance in DMD 1.5 MB
P.147 Muntoni et al. TOTAL Golo 6-year Follow-up 2.2 MB
P.149 Muntoni et al. Pulmonary Golo 6-year Follow-up 806.7 KB
P.304 Lowes et al. JOURNEY Study Design LGMD 889.2 KB
LBP.17 Potter et al. Supplement - Rat Myocardial 52 week data LBA 2.6 MB
LBP.17 Potter et al. Rat Myocardial 52 week data LBA 2.4 MB
09/11/23 at 8:40 AM EDT
Morgan Stanley 21st Annual Global Healthcare Conference
Click here for webcast
08/02/23 at 4:30 PM EDT
Sarepta Therapeutics Second Quarter 2023 Earnings Call
Click here for webcast
2Q 2023 Forward Looking Statement 190.1 KB
07/10/23 at 11:00 AM EDT
Cowen's 2nd Annual RNA Therapeutics Summit
Click here for webcast
06/22/23 at 4:30 PM EDT
ELEVIDYS (delandistrogene moxeparvovec-rokl) FDA Accelerated Approval Call
Click here for webcast
ELEVIDYS FDA Accelerated Approval Presentation 3.6 MB
05/16 - 05/20/23
American Society of Gene and Cell Therapy 26th Annual Meeting (ASGCT 2023)
Raper et al. Step Gradient Development for Full Particle Enrichment of AAV 1.1
MB
Potter et al. Safety and Efficacy of Pre-Trmt with Imlifidase Prior to AAV-Based
Gene Therapy 1.2 MB
Potter et al. Eval Pharmacol and Efficacy of SRP-9001 in Young and Aged DMD mdx
Rats 8.7 MB
Goedeker et al. Mgmt of Patients Following Investig SRP-9001 for DMD Delphi
Panel Consensus 444.7 KB
East et al. PKPD Modeling to Inform Clinical Dev of an AAV Gene Transfer Therapy
for DMD 980 KB
Potter et al. Vector Shedding in Patients with DMD 1.6 MB
Lowes et al. SRP-9001-101 in Patients with DMD 4 year Update 1.1 MB
05/02/23 at 4:30 PM EDT
Sarepta Therapeutics First Quarter 2023 Earnings Call
Click here for webcast
1Q 2023 Forward Looking Statement 258.8 KB
03/19 - 03/22/23
2023 MDA Clinical and Scientific Conference
P.39 Iannaccone et al. Interim Safety and Musc Biopsy Ph3 ESSENCE (Casimersen)
7.8 MB
P.87 Smith et al. Analysis of Vector Shedding Following trmt with Del Mox 628.5
KB
P.87 Smith et al. Supplement - Analysis of Vector Shedding Following trmt with
Del Mox 346.1 KB
P.97 Shieh et al. A Ph2 Clinical Trial Eval Safety and Efficacy of Del Mox in
DMD 524.9 KB
P.100 Singh et al. EMBARK Ph3 Clinical Trial Eval Safety and Efficacy of Del Mox
in DMD Design and Baseline Char 501.9 KB
P.106 Proud et al. Integ Analysis of Data from Clinical Trials of Del Mox in DMD
13.6 MB
P.177 Ricchetti-Masterson et al. Nat Hist of BMD A Living Systematic Literature
Review 785.6 KB
P.183 McDonald et al. Survival in Eteplirsen trtd v. DMD Nat Hist pts an
Indirect Trmt Comparison Using RWD 4.7 MB
P.185 McDonald et al. Interim Analysis of EVOLVE LT Obvs Study Eval Etep Golo
Casi in Routine Clinical Practice 1.2 MB
P.211 McDonald et al. Interim Analysis of EVOLVE Eval Etep Golo Casi in pts
under 7 yo in Routine Clinical Practice 582.5 KB
P.249 Wier et al. Eval Pharmacol and Efficacy of Del Mox in Young and Aged
DMDmdx rats 1.4 MB
P.249 Wier et al. Supplement - Eval Pharmacol and Efficacy of Del Mox in Young
and Aged DMDmdx rats 7.1 MB
ePoster East et al. PKPD Modeling to Inform Clinical Dev of AAV Gene Transfer
Therapy for DMD 703.9 KB
Oral P.53 Goedeker et al. Mgmt of Select AEs Following Del Mox in pts with DMD
Delphi Panel Consensus Considerations 1.6 MB
Oral Presentation Goedeker et al. Mgmt of Select AEs Following Del Mox in pts
with DMD Delphi Panel Consensus Considerations 878.9 KB
Oral P.96 Mendell et al. Long-term Safety and Efficacy in pts with DMD 4yrs Post
Trmt with Del Mox 2 MB
Oral P.107 Proud et al. One-year Data from ENDEAVOR Ph1B Trial of Del Mox in DMD
pts 810.2 KB
03/16/23 at 4:30 PM EDT
Sarepta Therapeutics SRP-9001 BLA Update Call
Click here for webcast
Forward Looking Statement 227.6 KB
02/28/23 at 4:30 PM EST
Sarepta Therapeutics Fourth Quarter and Full-Year 2022 Earnings Call
Click here for webcast
4Q 2022 Forward Looking Statement 263.9 KB
01/09/23 at 1:30 PM EST
Sarepta Therapeutics at the 41st Annual J.P. Morgan Healthcare Conference
Presentation and Q&A
Click here for webcast
Sarepta Therapeutics 2023 JPMorgan Conference 3.1 MB
12/01/22 at 2:15 PM EST
Evercore ISI HealthCONx Conference
Click here for webcast
11/02/22 at 4:30 PM EDT
Sarepta Therapeutics Third Quarter 2022 Earnings Call
Click here for webcast
3Q 2022 Forward Looking Statement 194 KB
10/11 - 10/15/22
27th International Hybrid Annual Congress of the World Muscle Society 2022
Congress (WMS 2022)
P.64 Lowes et al. Validity of remote eval of NSAA in DMD 1.5 MB
P.70 Lowes et al. Rasch Analysis of the PROMIS Parent Proxy Mobility Item Bank
523.4 KB
VP.82 East et al. PKPD modelling to inform clin dev of AAV gtx for DMD 654.4 KB
VP.57 Mendell et al. SRP-9001-101 in DMD 4-year update 1.1 MB
P.197 Potter et al. Eval pharmacol and efficacy of SRP-9001 in DMD mdx rats 8.9
MB
P.170 Rodino-Klapac et al. Safety Expression Functional Outcomes SRP-9003-101
LGMD2E 3.3 MB
P.132 Iannaccone et al. Interim Results From the Ph3 ESSENCE Trial (Casimersen)
1.3 MB
P.129 Zaidman et al. SRP-9001-103 (ENDEAVOR) in DMD 1-year data 707.7 KB
P.128 Zaidman et al. Integrated Analysis of SRP-9001 in DMD 521.2 KB
LSP.36 Shieh et al. A Ph 2 clinical trial eval safety and efficacy of SRP-9001
867.4 KB
LSP.35 Malhotra et al. Analysis of vector shedding following treatment with
SRP-9001 631.9 KB
LSVP.31 Ricchetti-Masterson et al. Interim Analysis of EVOLVE 351.7 KB
LSP.30 Muntoni et al. Survival in Eteplirsen-Treated vs DMD Nat Hist Controls
709.5 KB
LSP.22 Audhya et al. Estimating Health State Utilities in DMD Using EQ-5D and
HUI 553.8 KB
09/12/22 at 12:30 PM EDT
Morgan Stanley 20th Annual Global Healthcare Conference
Click here for webcast
08/02/22 at 4:30 PM EDT
Sarepta Therapeutics Second Quarter 2022 Earnings Call
Click here for webcast
2Q 2022 Forward Looking Statement 256.9 KB
07/06/22 at 8:30 AM EDT
SRP-9001: New Clinical Data and Integrated Analysis
Click here for webcast
SRP-9001 New Clinical Data and Integrated Analysis 1.3 MB
07/05 - 07/09/22
17th International Congress on Neuromuscular Diseases (ICNMD 2022)
Zaidman et al. SRP-9001-103 (ENDEAVOR) in DMD 1-year data 1.2 MB
Zaidman et al. Integrated Analysis of SRP-9001 in DMD 1.1 MB
Mendell et al. SRP-9001-101 in DMD 4-year update 635.1 KB
Rodino-Klapac et al. Safety Expression Functional Outcomes SRP-9003-101 LGMD2E 1
MB
Mercuri et al. Safety tol and PK of etep in pts 6-48 mon with DMD 448.6 KB
06/23/22 at 4:15 PM EDT
Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne
Click here for webcast
06/14/22 at 1:00 PM EDT
Goldman Sachs 43rd Annual Global Healthcare Conference
Click here for webcast

--------------------------------------------------------------------------------

This section of our website may contain dated or archived information which
should not be considered current and may no longer be accurate. For current
information, you are encouraged to review our most recent official corporate
documents on file with the U.S. Securities and Exchange Commission.

This website, including releases and presentations posted on it, contains
"forward-looking statements." Any statements that are not statements of
historical fact may be deemed to be forward-looking statements. Words such as
“believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,”
“look,” “potential,” “possible” and similar expressions are intended to identify
forward-looking statements. These forward‐looking statements involve risks and
uncertainties, many of which are beyond our control and are based on our current
beliefs, expectations and assumptions regarding our business. Actual results and
financial condition could materially differ from those stated or implied by
these forward‐looking statements as a result of such risks and uncertainties and
could materially and adversely affect our business, results of operations and
trading price. Potential known risk factors include those risks identified under
the heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K
and most recent Quarterly Report on Form 10‐Q filed with the Securities and
Exchange Commission (SEC) and in its other SEC filings.

For a detailed and updated description of risks and uncertainties Sarepta faces,
you are encouraged to review Sarepta's filings with the SEC. We caution
investors not to place considerable reliance on the forward‐looking statements
contained in this website. Other than as required under applicable law, Sarepta
does not undertake any obligation to publicly update its forward‐looking
statements.

--------------------------------------------------------------------------------

TOOLKIT

Print Page | Email Alerts | RSS Feeds | Contacts

* Twitter
* LinkedIn
* Instagram
* Facebook

MAIN NAVIGATION

FOOTER UTILITY NAV

* Privacy Policy
* Terms of Use
* EU-U.S. and Swiss-U.S. Privacy Shield Policy

investorrelations.sarepta.com Open in urlscan Pro 2a02:26f0:c6::210:6563 Public Scan

Form analysis 1 forms found in the DOM

GET /search

Text Content

investorrelations.sarepta.com Open in urlscan Pro
2a02:26f0:c6::210:6563 Public Scan

Form analysis
1 forms found in the DOM